À retenir
In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Salt substitutes with less sodium and more potassium have been shown to lower blood pressure, but the abstract's background says their effects on cardiovascular and safety outcomes were uncertain. The trial set out to test, in people at high risk, whether using a salt substitute instead of ordinary salt would mean fewer strokes (the primary outcome), fewer major adverse cardiovascular events and fewer deaths from any cause (secondary outcomes). It also tracked clinical hyperkalemia as the safety outcome, to see whether adding potassium to the diet caused harm.
Population et méthode
SSaSS was an open-label, cluster-randomized trial: 600 villages in rural China were randomly assigned 1:1, and the unit of randomization was the village rather than the person. Participants had a history of stroke, or were 60 years of age or older and had high blood pressure. In intervention villages participants used a salt substitute made of 75% sodium chloride and 25% potassium chloride by mass; in control villages they continued with regular salt, 100% sodium chloride. A total of 20,995 people were enrolled. Their mean age was 65.4 years, 49.5% were female, 72.6% had a history of stroke and 88.4% a history of hypertension. The National Health and Medical Research Council of Australia funded the trial. The abstract does not describe how the salt was supplied or how use was checked, and full details are not in the abstract.
The primary outcome was stroke, the secondary outcomes were major adverse cardiovascular events and death from any cause, and the safety outcome was clinical hyperkalemia. Mean follow-up was 4.74 years. Results are given as events per 1000 person-years and compared between groups as rate ratios with 95% confidence intervals and P values. The abstract does not describe the statistical model, including how clustering by village was handled, or how outcomes were confirmed.
Résultats
- 1Stroke was less frequent with the salt substitute: 29.14 events versus 33.65 events per 1000 person-years with regular salt, a rate ratio of 0.86 (95% CI 0.77 to 0.96; P = 0.006).
- 2Major adverse cardiovascular events were also less frequent: 49.09 events versus 56.29 events per 1000 person-years, a rate ratio of 0.87 (95% CI 0.80 to 0.94; P<0.001).
- 3Death from any cause was lower too: 39.28 events versus 44.61 events per 1000 person-years, a rate ratio of 0.88 (95% CI 0.82 to 0.95; P<0.001).
- 4The potassium did not produce a significant excess of serious harm from hyperkalemia (high blood potassium): serious adverse events attributed to it occurred at 3.35 events versus 3.30 events per 1000 person-years, a rate ratio of 1.04 (95% CI 0.80 to 1.37; P = 0.76). The upper end of that interval leaves room for a modest increase.
Limites et incertitude
- 1The trial was open-label, as the abstract states, so villagers knew which salt they were using. That matters most for outcomes that depend on how people notice symptoms or seek care; the abstract does not say how outcomes were confirmed.
- 2Our observation: the participants were older adults in rural China, mostly with a past stroke (72.6%) and hypertension (88.4%), so the result should not be assumed to hold in younger people, people with normal blood pressure, or places with different diets and food supplies.
- 3Our observation: the substitute lowered sodium and raised potassium at the same time, so the trial cannot say which change drove the benefit. Villages, not individuals, were randomized, which makes the effective sample smaller than 20,995 people, and the abstract does not say how the analysis accounted for that.
- 4Our observation: the safety result covers serious adverse events attributed to hyperkalemia, which were uncommon (3.35 events per 1000 person-years in the salt substitute group). The abstract does not say how hyperkalemia was detected or whether people with kidney disease were enrolled, so it cannot show how the substitute behaves in people at high risk of high potassium. This reading rests on the abstract alone.
Mise en perspective
For older adults with high blood pressure or a past stroke, this large randomized trial shows that swapping ordinary salt for a potassium-enriched substitute lowered the rates of stroke, major cardiovascular events and death over several years, at least in a setting like rural China, without a significant rise in serious hyperkalemia events.
That safety result is reassuring but not a guarantee: because the substitute adds potassium, anyone with kidney disease or taking medicines that affect potassium levels should ask a clinician before switching, since the abstract does not say whether such people were enrolled. A salt substitute does not replace prescribed blood pressure treatment, and the result does not show the same benefit for younger or healthy people. Confidence in the benefit is good for this kind of population.
Vos données
Wearables cannot see how much sodium or potassium you eat, so the useful data are home blood pressure readings: use the same validated upper-arm cuff, at the same time of day, seated and rested, and compare weekly averages over several weeks before and after a change in diet rather than single readings. A food log can show the sodium in what you eat. A watch's stress or heart-rate score cannot tell you whether a salt substitute is safe for you; that is a question for a clinician.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Sources et attribution
Effect of Salt Substitution on Cardiovascular Events and Death
The New England Journal of Medicine · 2021-09-16
DOI: 10.1056/NEJMoa2105675 ↗PubMed · 34459569 ↗Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people
Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.
Journal of the American Heart Association
Five exercise types lowered resting blood pressure, isometric training the most
Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.
British Journal of Sports Medicine
Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation
Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.
The New England Journal of Medicine
Evolocumab added to statins lowered LDL by 59% and reduced cardiovascular events
In 27,564 people with atherosclerotic cardiovascular disease already on a statin, adding evolocumab lowered LDL cholesterol by 59% versus placebo at 48 weeks and reduced the primary composite of cardiovascular events to 9.8% from 11.3% over a median 2.2 years (HR 0.85, 95% CI 0.79 to 0.92). Amgen funded the trial, follow-up was short, and only people with established disease took part, so the result does not speak to healthy people or to long-term safety.
The New England Journal of Medicine

